NM
Natalie Marchevsky
Research areas: Medicine · Infectious Diseases · SARS-CoV-2 and COVID-19 Research · Vaccine Coverage and Hesitancy · COVID-19 Clinical Research Studies
0000-0003-1055-0033
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (32)
- Comparable safety and humoral immunogenicity of delayed versus delayed fractional boosting with blood-stage malaria RH5.1/Matrix-M vaccine Save
- Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials Save
- Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil Save
- Optimising DTwP-Containing Vaccine Infant Immunisation Schedules (OptImms): Two Open-Label Non-Inferiority Randomised Controlled Trials in Uganda and Nepal Save
- Preliminary safety data from a randomised trial of early versus standard timing of administration of measles-rubella vaccine in Ugandan infants Save
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006) Save
- A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered with Group B Meningococcal Vaccine Save
- Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection Save
- Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults Save
- An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females Save
- Colorectal Endoscopic Stenting Trial (CReST) for obstructing left-sided colorectal cancer: Randomized clinical trial Save
- Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV Save
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial Save
- Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (Nature Medicine, (2021), 27, 2, (279-288), 10.1038/s41591-020-01179-4) Save
- Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (Nature Medicine, (2021), 27, 2, (270-278), 10.1038/s41591-020-01194-5) Save
- Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses Save
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil Save
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial Save
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7) Save
- Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses Save